Elanco Animal Health Incorporated (ELAN)
ELAN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$22.41
-0.67% on the day
Market cap
$11.2B
Large cap
Revenue · 2025
$4.7B
+6.2% on 2024
Net income · 2025
-$232.0M
-4.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ELAN on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001739104 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.7B |
| Net income | -$232.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | -4.9% |
| Operating margin | Operating income not reported |
| Revenue growth | +6.2% |
| Cash | $545.0M |
| Total assets | $13.4B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2020-12-02 |
| Latest annual report 10-K FOR THE YEAR ENDED DECEMBER 31, 2025 | 10-K | 2026-02-24 |
| Latest quarterly / interim 10-Q FOR THE PERIOD ENDED JUNE 30, 2026 | 10-Q | 2026-08-05 |
| Latest current report 8-K DATED AUGUST 5, 2026 | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-04-08 |
Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.8% |
| 1 month | -2.0% |
| 3 months | -13.1% |
| Year to date | -0.4% |
| 1 year | +12.5% |
| From 52-week high | -16.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RDY | Dr. Reddy's Laboratories Ltd | $12.77 | -0.39% | $10.7B |
| BMRN | BioMarin Pharmaceutical Inc. | $54.38 | -1.82% | $10.5B |
| MDGL | Madrigal Pharmaceuticals Inc. | $452.12 | -3.22% | $10.4B |
| BBIO | BridgeBio Pharma Inc. | $63.30 | -3.73% | $12.4B |
| SMMT | Summit Therapeutics Inc. Common Stock | $15.52 | -9.40% | $12.4B |
| CORT | Corcept Therapeutics Incorporated | $117.80 | -2.80% | $12.7B |
| JAZZ | Jazz Pharmaceuticals plc Common Stock (Ireland) | $210.39 | -2.93% | $13.7B |
| PTGX | Protagonist Therapeutics Inc. | $138.49 | -4.41% | $9.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier